SELLAS Life Sciences Group Debt to Equity

The latest debt-to-equity ratio for SLS is 0.01. That is below the Healthcare sector average of 0.3. Investors often review this figure alongside SELLAS Life Sciences Group's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, SLS currently prints 0.01 for debt-to-equity ratio, while the sector average sits near 0.3. That is roughly 98.2% below the sector mean. Large gaps often invite a closer look at SELLAS Life Sciences Group's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.01 for SELLAS Life Sciences Group is not 'good' or 'bad' on its own. Compare it with the peer average (0.3) and with SLS's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting SLS's debt-to-equity ratio (0.01), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack SELLAS Life Sciences Group's debt-to-equity ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.